Physician profile
Niraj K Gupta
NPI 1790717510
$3,887.38
in general payments reported to CMS, 2019-2025
42 companies · $308 in 2025
The $308 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,825 · 2020: $609 · 2021: $245 · 2022: $578 · 2023: $181 · 2024: $142 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $630.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $394.61 | 2019-2022 | |
| Pfizer INC. | $274.05 | 2019-2022 | |
| Novocure Gmbh | $250.00 | 2022 | |
| Genentech USA, INC. | $223.60 | 2019-2020 | |
| Janssen Biotech, INC. | $192.30 | 2019-2024 | Rybrevant |
| E.R. Squibb & Sons, L.L.C. | $180.10 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $178.17 | 2019-2024 | Keytruda, Welireg |
| Athenex Pharmaceutical Division, LLC | $175.00 | 2020 | |
| Neurocrine Biosciences, INC. | $168.59 | 2025 | |
| Genzyme Corporation | $159.57 | 2019 | |
| Novartis Pharmaceuticals Corporation | $147.14 | 2019-2025 | |
| Asd Specialty Healthcare, LLC | $142.32 | 2019 | |
| Tempus Ai, INC | $133.50 | 2024-2025 | Xt Cdx |
| Mirati Therapeutics, INC. | $113.69 | 2023 | Krazati |
| Comsort, INC | $100.00 | 2019 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niraj Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.